Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Polycystic Ovary Syndrome 2Peripheral Nervous System Diseases 2Neurofibromatosis 1 2Lung Neoplasms 2Liver Neoplasms 2Weight Loss 1Tongue Neoplasms 1Stomatitis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Renal Insufficiency, Chronic 1Renal Artery Obstruction 1Radiation-Induced Mucositis 1Pulmonary Embolism 1Primary Graft Dysfunction 1Ototoxicity 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Myofibroma 1Muscular Atrophy 1Mucositis 1Melanoma 1Lymphoma, Non-Hodgkin 1Liver Failure, Acute 1Liver Failure 1Liver Diseases 1Insulin Resistance 1Inflammation 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × Acetylcysteine × Clear all
NCT02908750 2022-11-14

Study to Assess the Effect of Osimertinib (TAGRISSOâ„¢ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

AstraZeneca

Phase 1 Completed
24 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡